ReviewGenes & development2012
Melanoma: from mutations to medicine.
Review in Genes & development, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 258 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
258 citing papers in PubMed, 2 syntheses or guidelines pooled it, 474 citations in OpenAlex.
- Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.Cells · 2024Pooled it
- Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database.The Journal of investigative dermatology · 2015Pooled it
- Regulatory roles of N6-methyladenosine methylation factors in melanoma invasion and metastasis (Review).Oncology letters · 2026Review
- Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.International journal of molecular sciences · 2026Article
- Evaluation of Natural Polyphenols Encapsulated in Multiparticulate Drug Delivery Systems as Potential Therapeutics for Cutaneous Melanoma.Journal of functional biomaterials · 2026Article
- Article
- Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026Review
- Thinking beyond immunotherapy: implementing a multimodal care plan to facilitate extended survival in stage IV melanoma.Melanoma research · 2026Article
- Amino Acid Metabolism of the Skin: Control by Specific Enzymes and Contribution to Protective Functions.Metabolites · 2025Review
- Targeted synthesis of a trimethoxyphenyltetrahydropyrimidine analogue designed as a DNA intercalator:RSC advances · 2025Article
- A descriptive review of common dermatological diseases encountered by manual therapy providers.The Journal of the Canadian Chiropractic Association · 2025Article
- Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to SensitizeInternational journal of molecular sciences · 2025Article
- Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors.Molecules (Basel, Switzerland) · 2024Review
- Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ.Journal of clinical medicine · 2024Article
- A Combination of Cardamonin and Doxorubicin Selectively Affect Cell Viability of Melanoma Cells: An In Vitro Study.Antioxidants (Basel, Switzerland) · 2024Article
- Integration analysis of single-cell transcriptome reveals specific monocyte subsets associated with melanoma brain and leptomeningeal metastasis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.ACS omega · 2024Review
- CircRTTN upregulates EPHA2 to aggravate the malignant process of melanoma via sponging miR-890.Histology and histopathology · 2024Article
- Nodular Melanoma in a 53-year-old Male with Glioblastoma Multiforme: A Rare Case Report.Acta medica Philippina · 2024Article
- Anoectochilusroxburghii extract down-regulates METTL3 to reduce RNA mJournal of Cancer · 2024Article
198 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Melanoma is often considered one of the most aggressive and treatment-resistant human cancers. It is a disease that, due to the presence of melanin pigment, was accurately diagnosed earlier than most other malignancies and that has been subjected to countless therapeutic strategies. Aside from early surgical resection, no therapeutic modality has been found to afford a high likelihood of curative outcome. However, discoveries reported in recent years have revealed a near avalanche of breakthroughs in the melanoma field-breakthroughs that span fundamental understanding of the molecular basis of the disease all the way to new therapeutic strategies that produce unquestionable clinical benefit. These discoveries have been born from the successful fruits of numerous researchers working in many-sometimes-related, although also distinct-biomedical disciplines. Discoveries of frequent mutations involving BRAF(V600E), developmental and oncogenic roles for the microphthalmia-associated transcription factor (MITF) pathway, clinical efficacy of BRAF-targeted small molecules, and emerging mechanisms underlying resistance to targeted therapeutics represent just a sample of the findings that have created a striking inflection in the quest for clinically meaningful progress in the melanoma field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.